Benzodiazepine bromodomain inhibitor
US-2017197972-A1 · Jul 13, 2017 · US
Selective bromodomain inhibition of fungal Bdf1
US10918647B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10918647-B2 |
| Application number | US-201716320412-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2017 |
| Priority date | Jul 26, 2016 |
| Publication date | Feb 16, 2021 |
| Grant date | Feb 16, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides antifungal compounds, antifungal compositions, and intermediates for the preparation of antifungal compounds and antifungal compositions. The invention also provides methods of inhibiting fungi and methods of treating fungal infections, for example, with a compound or composition described herein. The antifungal compositions can include antifungal adjuvants such as essential oils or essential oil extracts, which adjuvants further improve the antifungal activity of the compositions.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of MS4 and MS5: 2. A pharmaceutical composition comprising a compound of claim 1 , a second antifungal drug, and a pharmaceutically acceptable diluent, excipient, or carrier. 3. A pharmaceutical composition comprising a compound of claim 1 and an antifungal adjuvant. 4. The pharmaceutical composition of claim 3 wherein the antifungal adjuvant is an essential oil or an essential oil extract, wherein the essential oil or essential oil extract is selected from the group consisting of sweet orange, Mentha arvensis , peppermint, cedarwood, lemon, Eucalyptus globulus, Litsea cubeba , clove, spearmint, nutmeg, cinnamon, basil, bay leaf, and eugenol. 5. A method of treating a fungal infection in a subject in need thereof comprising administering to the subject an effective antifungal amount of a compound that inhibits one or both fungal bromodomain proteins, wherein the compound is a compound of claim 1 and the fungal infection is thereby treated. 6. The method of claim 5 wherein the compound is administered, concurrently or sequentially, in combination with a second antifungal drug. 7. The method of claim 6 wherein the second antifungal drug is amphotericin, anidulafungin, caspofungin, clotrimazole, fluconazole, flucytosine, itraconazole, ketoconazole, micafungin, miconazole, posaconazole, or voriconazole.
Assignees
Inventors
Classifications
Inorganic compounds · CPC title
Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin · CPC title
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10918647B2 cover?
- The invention provides antifungal compounds, antifungal compositions, and intermediates for the preparation of antifungal compounds and antifungal compositions. The invention also provides methods of inhibiting fungi and methods of treating fungal infections, for example, with a compound or composition described herein. The antifungal compositions can include antifungal adjuvants such as essent…
- Who is the assignee on this patent?
- Univ Southern California, Centre Nat Rech Scient, Univ Grenoble Alpes, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/554. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).